Cellectis S.A.(CLLS)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-12-31.

Cellectis S.A. (CLLS) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CLLS at 26.6/100 on a 32-signal composite quality model, placing it at rank #2,610 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Cellectis S.A. reports quarterly revenue of $72.9M, net income of $-67.6M. Top institutional holders of CLLS by reported 13-F value include B Group, Long Focus Capital Management, UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME, based on the most recent SEC filings. CLLS trades on the Nasdaq exchange and files with the SEC under CIK 1627281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CLLS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cellectis S.A. directly from SEC EDGAR.